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Abstract
Bullous systemic lupus erythematosus is a rare distinctive subepidermal bullous disease seen 
in patients with systemic lupus erythematosus (SLE). It has characteristical clinic, pathologic, 
and immunologic findings including antibodies to type VII collagen, laminin 332, laminin 
331, and bullous pemphigoid antigen 230. Clinical presentation combined with histopathol-
ogy, immunological testing, and concomitant diagnosis of SLE according to the criteria of 
American College of Rheumatology, are required to distinguish bullous SLE from these 
bullous diseases. In patients with bullous SLE, SLE disease progression and complications 
may be worse. Cicatricial pemphigoid is a chronic subepidermal blistering disease which 
is characterized by erosive lesions of mucous membranes and skin. Pathogenesis of cicatri-
cial pemphigoid is characterized by linear deposition of Immunoglobulin G, A, or comple-
ment 3 along the epithelial basement membrane zone. The main target antigens are bullous 
pemphigoid antigens 180–230, laminin 331–332, type VII collagen, and β-4 integrin subunit. 
Cicatricial pemphigoid may lead to serious complications such as blindness and airway 
obstruction. Herein, clinical, histological, immunopathological features, the diagnosis and 
treatment of bullous SLE and cicatricial pemphigoid diseases are mentioned to raise aware-
ness among the dermatologists about this important but rare heterogeneous bullous disease.
Keywords: bullous dermatosis, bullous systemic lupus erythematosus, nephritis, 
cicatricial pemphigoid, mucous membrane pemphigoid, ocular, oral, subepithelial 
autoimmune disease
1. Bullous systemic lupus erythematosus
1.1. Introduction
It has been reported that numerous cutaneous lesions might be seen in 59–76% of patients 
with systemic lupus erythematosus (SLE) [1, 2]. But, blistering lesions are relatively 
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uncommon, which is approximately less than 1% of all cutaneous lesions seen in SLE 
[2]. Patients with SLE may have intense inflammation and basal vacuolar degeneration 
that induce blister formation [3]. However, SLE with concomitant separate bullae is rare. 
Bullous SLE (BSLE) is a heterogeneous disease that has distinctive clinical and histologic 
features [1].
BSLE is caused by several defined autoantibodies. Primary autoantibodies are anti-type VII 
collagen antibody [4] and antibodies against laminin (Lam)-332, Lam-331, and bullous pem-
phigoid (BP) antigen-230 have been identified later [5, 6].
Rupture of blisters leads to skin loss and erosions that cause significant dehydration, loss 
of electrolytes, and proteins, particularly if there is extensive body surface involvement. 
Moreover, if the oral mucosa, and gastrointestinal system are affected, the patient may not 
be able to take adequate food and medication. Thus, these changes cause immunosuppres-
sion, and eventually infections and sepsis as well. So, it is important to diagnose and treat 
carefully all autoimmune bullous dermatoses, as they have fatal complications and mor-
bidities [7].
BSLE is characterized by subepidermal, transient, tense vesiculobullous eruptions located on 
any area of the body. Contrast to BSLE, in all types of cutaneous lupus erythematosus (CLE), 
vesiculobullous lesions are typically polycyclic erosions with an advancing blistering border 
on sun-exposed areas of the body [8–11]. Beyond the clinical presentations, pathogenesis 
and histopathological features are quite different among those types of diseases. In CLEs, 
a genetic base originated from variations in multiple loci leads to susceptibility to LE and 
disease activity is provoked by exogenous or endogenous triggers. The best known trigger 
is exposure to ultraviolet radiation [8, 12–15]. BSLE is associated with an increased preva-
lence of the human leukocyte antigen (HLA) class II DR2 haplotype-like SLE. Furthermore, 
it has also been found that the DR2-associated DRB1*1501 allele can be seen in patients who 
develop antibodies to type VII collagen [16]. However, triggering factors have not been 
exactly defined in BSLE [9].
Histologic findings of CLEs such as epidermal atrophy, hydropic changes, apoptotic keratino-
cytes, and mucin deposits are not expected in BSLE either. Direct immunofluorescence (DIF) 
study in CLEs and BSLE may be similar while IIF studies show different findings [3, 14]. Thus, 
differentiation of BSLE from other types of CLEs can be possible based on clinical features, 
histopathology, and immunohistochemical examinations.
Dermatitis herpetiformis (DH), BP, epidermolysis bullosa acquisita (EBA), and linear 
immunoglobulin (Ig) A bullous dermatoses (LABD) are included in the differential diag-
nosis of BSLE due to the presence of similarities in clinic, histology, and immunopathol-
ogy [17]. Briefly, DH can be excluded by light microscopy and direct immunofluorescence 
(DIF) method. BSLE, BP, and EBA have similar DIF patterns. Salt-split skin test demon-
strates IgG antibodies on the epidermal side (roof pattern) of the split skin in BP unlike 
EBA and BSLE in which IgG antibodies bind on the dermal side (floor pattern) of the split 
skin. Thus, differentiation between BSLE and EBA is not possible by demonstration of der-
mal binding in salt-split skin test. Presence of ACR criteria for the diagnosis of SLE points 
the way to BSLE [6, 18].
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To diagnose BSLE, fulfillment of the criteria of SLE is required. The Systemic Lupus International 
Collaborating Clinic (SLICC) group recently validated the 1997 American College of 
Rheumatology (ACR) revised criteria for SLE [19, 20]. Also, a new classification was defined by 
SLICC group. Misdiagnosis of SLE is less likely to occur through this new classification system. 
During the vesiculobullous presentation of BSLE, also systemic symptoms of SLE may get worse. 
Particularly, nephritis has been found associated to BSLE in many cases [12, 21–23]. However, the 
exact underlying mechanism has not been found yet.
A thorough history, the clinical presentation, fulfilling the criteria of ACR for SLE and histo-
pathological findings along with DIF, IIF, and ELISA can be helpful in diagnosing most cases 
of BSLE [24].
BSLE lesions are usually recalcitrant to the systemic corticosteroids which are used to 
treat the other manifestations of SLE [1]. The corner stone treatment of BSLE is dapsone 
and response is rapid even with small doses [1, 5, 8]. However, sometimes for the patients 
who fail to respond to dapsone or have intolerance to dapsone or have significant systemic 
SLE involvement—includes nephritis—other medications such as systemic steroids or other 
immunomodulatory treatments such as azathioprine, methotrexate, antimalarial agents, 
mycophenolate mofetil (MMF), rituximab, and intravenous immunoglobulin (IVIG) may be 
needed [5, 6].
1.2. Epidemiology and history
BSLE is an uncommon, auto-antibody-mediated subepidermal bullous eruption occurring 
in patients with SLE [4, 5]. BSLE generally affects young females of all races especially in the 
second to fourth decades of life. There have been some reported cases in older patients or in 
children as well [10–13, 25]. Female dominance may be related to SLE. Furthermore, there has 
been no informed race predominance up to now [8].
There have been case reports on SLE presenting with hemorrhagic bullae on sun-exposed 
areas of the body of patients in the literature as early as in the late nineteenth century. The 
clinical photographs of a patient were published in 1961 by Tromovitch and Hyman. She was 
a 26-year-old woman with SLE and had hemorrhagic bullae on the extensor aspects of the 
arms and legs, which are thought to be bullae of bullous SLE. The histologic examination of 
the lesion revealed bullae containing polymorphonuclear cells and some lymphocytes. But in 
that time, DIF method was not available, and so it could not be performed as well [26]. Also, 
the first well-documented cases of BSLE were published by Hall et al. [27].
1.3. Immunopathogenesis
In BSLE, main autoantibodies are circulating anti-type VII collagen antibodies (noncollag-
enous domain (NC) 1 and 2). Type VII collagen is found in the basement membrane zone 
(BMZ) as an important element of anchoring fibrils, and maintains adhesion at the dermo-
epidermal junction (DEJ). Lam-332, and fibronectin, and especially NC1 domain of type 
VII collagen play important role in adhesion between the lamina densa, lamina lucida, and 
keratinocytes. Antibodies against type VII collagen are characteristic for both BSLE and 
EBA [4, 5].
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On the other hand, Chan et al. [6] has described other antigens related to immunopathogen-
esis of BSLE, which are namely Lam-331, Lam-332, and BP230. Although these molecules 
have been identified, the exact mechanism of autoimmunity in BSLE has yet to be elucidated, 
but it is theorized that antibodies to type VII collagen induces epitope spreading which leads 
to a secondary autoimmune response to the newly exposed targets in BSLE [1, 6, 8].
The NC1 domain of type VII collagen which consists of nine back-to-back homologous fibro-
nectin III-like subdomains and two flanking von Willebrand factor A-like domains, play 
a role in mediating interactions between type VII collagen and other matrix proteins [28]. 
The aminoterminal is also termed as cartilage matrix protein and antibodies to this cartilage 
matrix protein subdomain have been shown to induce dermoepidermal separation in vivo 
[29]. However, the pathogenic relevance of binding of autoantibodies to fibronectin III-like 
domains which was shown by immunoblotting has not been clarified yet [30]. In both ex 
vivo and in vivo studies demonstrated that the Fc portion of the autoantibody, activation of 
complement and release of elastase and gelatinase B, and reactive oxygen species released 
from activated neutrophils are important for blister formation in BSLE and EBA [13, 31–33]. 
As mentioned previously, in addition to complement activation, release of proteases and reac-
tive oxygen species from neutrophils has been shown to be fundamental for dermoepidermal 
separation induced by autoantibodies to type VII collagen ex vivo and in vivo in the pathogen-
esis of BSLE and EBA [11, 12, 20, 31, 32, 34].
An association between susceptibility to LE and autoimmunity to type VII collagen has been 
suspected for the reason of presence of autoantibodies to type VII collagen are part of the 
autoantibody repertoire of some patients with LE. Some authors claimed that autoantibodies 
to type VII collagen are seen in BSLE patients whereas some assumed there is a particular 
association between EBA and SLE. Also, there have been reported cases with concurrent SLE 
and EBA, EBA followed by SLE, and SLE followed by EBA [35–39]. Some patients with SLE 
were reported that had autoantibodies to type VII collagen documented by indirect immu-
nofluorescence (IIF) on split skin, immunoblotting, and immunoelectron microscopy (IEM) 
methods but no blistering disease [30].
There is a defined genetic base originating from variations in multiple loci in all types of CLEs. 
While this genetic base leads to susceptibility, exogenous, or endogenous triggers cause the 
presentation of the disease. The best known trigger is ultraviolet radiation [8, 12–15]. BSLE 
is associated with an increased prevalence of the HLA class II DR2 haplotype like SLE. This 
HLA-DR2 haplotype has been found associated with hyperimmunity [40]. Furthermore, anti-
bodies to type VII collagen in BSLE have also been found to be related to the antigen-presenting 
protein encoded by the DR2-associated DRB1*1501 allele. In other words, this allele was found 
only in BSLE patients [16]. It is possible that this genetic predisposition is responsible for an 
increased risk for development of autoimmunity to BMZ antigens. Overproduction of autoan-
tibodies by hyper-reactive B cells as a result of depressed T suppressor activity is an important 
feature of SLE [8].
In the patients with BSLE, all types of immunoglobulins can be present in the deposits around 
the DEJ, but the main identified type is IgG, followed by IgA and IgM [22–25]. Ig deposits 
may be found in biopsies of both lesional and perilesional skin, whereas complement is seen 
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in particular in perilesional region. Therefore, it is estimated that antibody-mediated acti-
vation of complement may lead to blister formation in BSLE patients [31]. Furthermore, in 
vitro studies have revealed that antibodies to type VII collagen lead to the activation of both 
complement and neutrophils causing the separation within the DEJ [9, 41, 42]. This prote-
olysis by leukocytes (induced by antibodies) was previously shown to occur in EBA disease, 
too [42]. Therefore, the immunopathological similarities and clinical presentations may cause 
diagnostic confusion between BSLE and EBA. Besides that, a distinct immunological diver-
gence could be shown by the determination of IgG subclass concentrations between EBA and 
BSLE. IgG2 and IgG3 deposits are found more often in BSLE patients, whereas IgG1 and IgG4 
deposits are observed in EBA patients. Even if the functional properties of IgG subclasses are 
well known, the specific contribution of each subclass to the pathogenesis in autoimmunity to 
type VII collagen is controversial [8, 22, 31, 41]. The determination of quantity and quality of 
circulating autoantibodies in the serum of patients is important for diagnosis, prognosis and 
treatment choices in autoimmune blistering dermatoses [31].
Recke et al. reported that recombinant anti-type VII collagen IgG3 antibody and, a lesser 
extent, IgG1 autoantibodies, were able to activate complement at the DEJ. IgG2 and IgG4 
antibodies were found inactive [31].
1.4. Clinical features
Clinically, BSLE is characterized by rapid onset, tense vesicles, and bullae on the erythema-
tous edematous plaques or normal skin and involves both sun-exposed and nonexposed areas 
in patients who meet the ACR revised criteria for SLE [2, 5, 7]. Bullae are usually multiple and 
may resemble bullae of BP, or may be small and grouped like DH lesions [1]. The lesions 
rapidly expand and have a predilection for face, vermillion border, upper trunk, supracla-
vicular region, and proximal extremities. Previously, it was thought that BSLE is seen only 
in sun-exposed areas, but now it has been shown that it can also affect any area of the body 
including the oral, pharyngeal, nasal, and vulvar mucous membranes [1, 2]. In addition, usu-
ally herpetiform vesicles are seen if there is facial involvement in BSLE. These lesions can be 
on malar areas with erythema and/or, perioral region, and vermilion border. Moreover, there 
have been some BSLE cases reported that present with only facial lesions as well [43, 44].
Other than vesicles or blisters, erythematous plaques with annular configuration, urticarial 
eruptions, erosions, crusted lesions and targetoid lesions can also be seen [5, 9]. But interest-
ingly, the primary lesions of chronic discoid, subacute, and acute LE are not commonly seen 
in BSLE [30]. Pruritus or burning sensation may or may not be present [8, 45]. If there is, 
pruritus is mild. In contrast to DH, lesions are less often seen on extensor surfaces, however 
some BSLE cases involving extensors such as hands, knees, or feet have been reported [46, 47].
There are many case reports showing that BSLE can be the initial presentation of SLE in both 
adults and children [11, 12, 21, 48–51]. Moreover, some authors estimated that BSLE may be 
associated with increased activity of SLE such as renal involvement, serositis such as peri-
carditis or pleuritis, pulmonary hemorrhage, cutaneous vasculitis, etc. [11, 12, 17, 21, 25, 44]. 
Nevertheless, the exact underlying mechanism of developing nephritis in BSLE is not clear. 
It is estimated that glomerular and/or tubular scarring causes injury to renal extracellular 
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matrix and by this injury, new expression of collagens, which does not locate in normal glom-
eruli, is oversynthesized and these antigens can trigger autoimmune reactions [2, 44, 52, 53]. 
Diagnosis of BSLE is important since BSLE may indicate development of lupus nephritis and 
resistance to treatment [12, 15, 44].
Most of the patients with BSLE have positive ANA tests. Moreover, anti-dsDNA, anti-Sm, 
anti-La/SS-B, anti-Ro/SS-A, and anticardiolipin antibodies may also be detected as well. Other 
laboratory findings that are related to SLE such as elevated erythrocyte sedimentation rate, 
hypocomplementemia, hematologic abnormalities (anemia, thrombocytopenia, leukopenia), 
and abnormal urinalysis (proteinuria or/and urine casts) can also be observed in BSLE [16].
1.5. Histopathology
Typically, histopathologic examination of early BSLE lesion shows inflammation and dermo-
epidermal separation at the BMZ. The epidermis is often intact. In the upper dermis, edema, 
and dermal papillary, neutrophilic microabscesses are seen similar to histopathological fea-
tures of DH [1, 8, 25, 30]. In most of the cases, neutrophils are not only seen in the papillae, but 
also form a continuous linear pattern which is concentrated in the upper dermis, in the blister 
cavity, and beneath and on the BMZ [30].
A subepidermal blistering and perivascular (around mid and upper dermal blood vessels) 
inflammatory infiltrate, including particularly lymphocytes, occasionally eosinophils and 
monocytes, are other histologic features of BSLE. Moreover, in some cases of leukocytoclasis, 
erythrocyte extravasation and necrosis of blood vessels, which belong to necrotizing vascu-
litis, may be seen. But in these cases, which have vasculitis characteristics, clinical features 
of vasculitis do not exist interestingly. Additionally, dermal vasculitis can be seen more fre-
quently in BSLE than DH [8, 17].
Some characteristic histopathological features of LE such as basal layer vacuolization, epider-
mal atrophy and thickening of the BMZ, mononuclear cell-predominant inflammation, mucin 
deposition in the reticular dermis are usually absent or rarely found in BSLE lesions [8, 17, 30].
1.6. Direct and indirect immunofluorescence techniques and immunoelectron 
microscopy
Classic immunopathologic features of BSLE by DIF examination are immune deposits in the 
upper dermis and along the BMZ and occasionally in upper dermal venules [8, 15, 30, 50]. 
These deposits include main Igs (IgG, IgA, and IgM), and complements. Complement pro-
teins are usually present in lesional skin but may be absent in clinically normal skin.
Among the aforementioned Ig types, IgG is most commonly seen, while IgM and IgA are pres-
ent in approximately 70% of cases. These depositions of Igs have two major patterns: granular 
in approximately 60% of cases and linear in 40%. In a few cases, fibrillar or thready patterns of 
depositions have been reported as well [8, 15, 53]. Furthermore, in some cases, a mixed pattern 
with a linear band of deposits and scattered granular deposits has been shown. In this linear 
pattern, deposits may be bandlike, thin, or widen. Regardless of the pattern of deposition, 
clinical and histopathologic features of BSLE does not differ, and they are steady [53].
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DIF study of BSLE lesions presents a resemblance of EBA; however, they are different from 
DH. Granular IgA deposits in DH disease are seen as confined to dermal papillae typically; 
however, in BSLE, it is not seen. Moreover, IgA deposits appear to be more common in BSLE 
than in SLE patients without blisters [4, 14, 27, 30, 45]. It should be kept in mind that DIF stud-
ies of BSLE can be similar to that of CLEs [17, 35].
The substrate used in IIF studies is normal human skin, and it is processed with patient serum 
to detect the circulating antibodies. In most cases of BSLE, autoantibodies to type VII collagen 
is detected by IIF studies; however, in some cases, negative staining may be seen, particu-
larly in the patients with granular Ig deposition pattern by DIF. DIF studies on salt-split skin 
from patients commonly show deposition along the dermal side, some beneath of the lamina 
densa, and some shows no deposition [36]. This heterogenicity of BSLE cases does not affect 
the clinical features in patients [53].
IEM shows deposits of Igs as a linear continuous band along the DEJ of dense granular reac-
tion products in the upper dermis beneath the basal lamina. Depositions may also be seen on 
the lamina densa and in the perivascular region and occasionally in the deeper dermis as well. 
The deposits do not localize in the lamina lucida, and thus, the possibility of a primary bul-
lous disease such as BP is excluded; because in BP, antibodies are against hemidesmosomal 
and/or lamina lucida antigens [1, 8].
1.7. ELISA and immunoblotting
Antibodies against 290- and 145-kDa autoantigens (type VII collagen) [36], can be extracted 
from the sera of BSLE patients via immunoblotting [28]. As mentioned previously, these auto-
antigens that are seen in BSLE patients are also target antigens in EBA.
Most recently developed method is ELISA, and the diagnosis of BSLE can be made faster and 
more accurate via ELISA. In ELISA method, NC1 and NC2 domain epitopes of type VII colla-
gen are used to find the presence of circulating antibodies in sera of patients. By this method, 
differential diagnosis between BSLE and EBA can be provided easily for the reason of EBA 
patients to have higher levels of IgG1 and IgG4, while BSLE patients have higher levels of 
IgG2 and IgG3 in their serum [23, 31, 37].
1.8. Diagnosis
The diagnostic criteria of BSLE was first proposed in 1983 [45] and was revised after the 
administration of salt split-skin immunofluorescence in 1988 [54]. These criteria include:
1. a diagnosis of SLE based on ACR criteria;
2. a nonscarring vesiculobullous eruption;
3. histopathologic features similar to DH-neutrophil-rich infiltrated subepidermal blisters in 
papillary dermis;
4. positive DIF of perilesional skin with deposition of IgG and/or IgM and IgA at the BMZ,
5. negative or positive IIF testing for circulating autoantibodies against the BMZ via the salt-
split skin technique;
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The BSLE patients were divided into three groups (Table 1) [15, 30] based on the presence 
of antibodies to type VII collagen and location of the antibodies against the BMZ [25, 30]. 
Distinguishing subtypes of BSLE based on clinical features is not possible, but could be per-
formed only through immunohistochemistry. Type I patients have circulating or deposited 
autoantibodies to type VII collagen, as determined by IIF or IEM and type I patients also have 
been fulfilling all criteria of ACR. However, type II patients do not demonstrate autoantibod-
ies to type VII collagen; they have autoantibodies against undetermined location of antigen 
or dermal antigen other than type VII collagen, and furthermore, these type II patients satisfy 
only one to four criteria of ACR [2, 30]. And, autoantibodies to type VII collagen can be shown 
bound to either epidermal or both dermal and epidermal in type III patients [30, 49].
Type I
Clinic Fulfilling all criteria of SLE of ACR; subepidermal, transient, tense vesiculobullous 
eruption located on any area of the body
Histopathology Infiltration of neutrophils in the upper dermis, dermal edema, subepidermal blister
DIF IgG, IgA, and IgM, complement at the BMZ
IIF Circulating autoantibodies to type VII collagen (+), positive or negative for dermal staining 
of salt-split skin
ELISA/immunoblotting Positive or negative reaction to 290 and 145 kDa proteins from human skin basement 
membrane extracts
IEM Ig deposits in upper dermis and beneath and on the lamina densa
Type II
Clinic Fulfilling one to four criteria of ACR; same as type I
Histopathology Same as type I
DIF Same as type I
IIF Circulating autoantibodies to type VII collagen (−), negative for staining of split skin
ELISA/immunoblotting Negative reaction to the 290 and 145 kDa proteins from basement membrane extracts
IEM Scattered granular deposits in the upper dermis, but none on or beneath the lamina densa
Type III
Clinic Same as type I
Histopathology Same as type I
DIF Same as type I
IIF Circulating autoantibodies to type VII collagen (+/−), positive for epidermal staining of 
salt-split skin
ELISA/immunoblotting Positive or negative reaction to 290 and 145 kDa proteins from basement membrane 
extracts
IEM Ig deposits in the epidermis, sometimes in the upper dermis and lamina densa
Table 1. Subtypes of bullous SLE.
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Because of similar features between BSLE and other immunobullous dermatoses, the correct 
diagnosis of BSLE could be done by sum of the clinical, histological, immunohistological, 
and IEM features and meeting the ACR criteria for SLE [8]. The criteria proposed by Camisa 
and Sharma were formed before IEM, ELISA, and immunoblotting techniques [54]. These 
methods which can detect circulating antibodies in serum provide more accurate diagnosis 
of BSLE [15, 55].
1.9. Differential diagnosis
As mentioned previously, blisters can be seen in all types of CLE including acute, subacute, and 
chronic CLE. But, these bullous lesions are different from BSLE in terms of their clinical, histologi-
cal, and pathogenetical features. In all types of CLEs, a genetic base originated from variations 
in multiple loci leads to susceptibility to LE and disease activity is provoked by exogenous or 
endogenous triggers. However, in the pathogenesis of BSLE, these genetic susceptibility or trig-
gering factors have not been mentioned clearly [8, 12, 14]. Blisters in CLEs are polycyclic erosions 
with an advancing blistering border and always seen over an erythematous base predominantly 
on sun-exposed parts of body. Subepidermal blister formation in CLEs is caused by extensive 
interface inflammation and basal layer vacuolization which can be seen in CLE [3]. Histologic 
findings of CLEs such as epidermal atrophy, hydropic changes, apoptotic keratinocytes, and 
mucin deposits are not expected in BSLE. DIF study in CLEs and BSLE may be similar, while IIF 
shows different findings [3, 14]. Thus, differentiation of BSLE from other types of CLEs can be 
done based on clinical features, histopathology, and immunohistochemical examinations [12, 15].
Lesions can mimic other vesiculobullous disease such as EBA, BP, DH and LABD [15]. There 
are two main clinical presentations of EBA: the classical (mechanobullous, non-inflammatory) 
and the inflammatory subtypes. In classic type of EBA, skin lesions appear over non-inflamed 
skin. It also has chronic course with skin fragility, usually resistant to therapy, and often 
causes to debilitating sequelae. The lesions heal with scarring and milia limited to the trauma-
prone skin surfaces [15, 56, 57]. However, lesions of inflammatory type of EBA present with 
transient tense bullae over inflamed skin like BSLE lesions. The similarity of clinical features 
between inflammatory type and BSLE can cause confusion in diagnosis, especially in patients 
with no known prior history of SLE. But there are some clues to differentiate; for instance, 
EBA is more common in the fourth and fifth decades of life and has usually older patients 
than patients with BSLE [31]. Clinically, in contrary to lesions of EBA which sometimes pres-
ents with fragile blisters appearing over hands, knuckles, elbows, knees, and sacrum like 
dystrophic type, lesions of BSLE are nonscarring, and milia or fragility of the skin on trauma-
exposed areas are not expected characteristics [10, 57]. Furthermore, hypo- or hyperpigmen-
tation may remain after healing as well [8]. Also, there is another subset of patients with 
predominant mucous membrane involvement, and indistinguishable from cicatricial pem-
phigoid (CP) clinically, presenting with blisters and scarring in the oral, ocular, vaginal, and 
other mucous membranes, leading to significant dysfunction of organs, and even death [7]. 
The histopathology of EBA is quite heterogeneous but has much less dermal inflammatory 
infiltrate in classic type of EBA in comparison to BSLE [8]. Immunopathological similarities 
and diagnostic challenge that exists between BSLE and EBA can be also surmountable by 
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IgG subclass concentration analysis. As mentioned previously, IgG2 and IgG3 deposits are 
more in BSLE patients, while IgG1 and IgG4 deposits are more often in EBA patients [8, 22, 
31, 41]. In addition, EBA has been related to many systemic diseases including hematologic, 
infectious, and endocrine conditions, autoimmune disorders, malignancies, and particularly 
inflammatory bowel diseases (IBD) [58]. EBA is a chronic autoimmune disease, oral mucosal 
involvement may be extensive, and more resistant to treatment with steroids, dapsone, and 
other immunomodulatory agents, whereas lesions of BSLE can recover completely with treat-
ment [56]. Also, occasionally some BSLE cases were reported with features of EBA [39, 59].
BP is one of the main diseases in the differential diagnosis of BSLE. BP is characterized by tense 
bullae, erosions, and crusts that arise on normal or erythematous skin on the entire body but 
mostly trunk, extremities. Bullae usually heal without scarring or milia formation and patients 
mostly have pruritus that may precede blistering by months [60]. BP is more common in elderly 
patients, especially over 65 years old [10]. Histopathological findings are subepidermal blisters 
with inflammatory cell infiltrate in the superficial dermis containing predominantly eosinophils. 
Neutrophilic microabscess does not exist contrast to BSLE [10]. It is thought that eosinophils have 
an important role in blister formation via degranulation at the BMZ. Early prebullous, urticarial-
type lesions may show eosinophilic spongiosis as well. About 70% of BP patients have elevated 
serum IgE and about 50% have blood eosinophilia. DIF study of perilesional skin shows linear 
deposits of complement C3 (90–100% of patients) and IgG (70–90% of patients) at the BMZ. It is 
important to know that if DIF is negative for C3, the diagnosis of BP is suspicious [61]. IIF study 
shows circulating IgG that binds the epidermal basement membrane in most cases. ELISA test 
for BP180 and BP230 antibodies is positive. The negative pemphigoid serologies by ELISA tests, 
incompatible histologic and IF findings help to differentiate BSLE from BP [8].
In patients with LE, all blistering eruptions may not be BSLE all the time. Additionally, these 
patients tend to have co-morbidities which need many medications that can lead to bullous drug 
reactions. Also, sometimes patients with a severe acute or subacute CLE may resemble the symp-
toms of erythema multiforme (Rowell syndrome) or toxic epidermal necrolysis (TEN). In these 
type of patients, the eruptions are expected to develop rapidly or evolve over several weeks. 
And also in TEN-like acute CLE, lesions start as diffuse or patchy erythema, more often on sun-
exposed part of body and later, and evolve into flaccid annular bullae rapidly. They also show 
positive Nikolsky sign, whereas in BSLE nikolsky sign is generally negative. Histopathology of 
these lesions show solitary necrotic keratinocytes at lower epidermis, junctional vacuolar degen-
eration, intensive periadnexal and perivascular lymphocytic infiltrates, thickened BMZ, the pres-
ence of plasma cells or mucin unlike TEN and BSLE [62, 63]. Furthermore, DIF examination of 
this LE lesions sometimes shows granular deposits of IgG and/or IgM, and less commonly IgA, at 
DEJ; but this could not be seen all the time, meanly a negative DIF does not rule the LE out [64].
In these patients with TEN-like CLE, often severe systemic disease involvements are seen 
such as lupus nephritis, or cerebritis, etc. The underlying mechanism of TEN-like CLE may 
be related to Fas-Fas ligand interactions, which have resulted in the massive keratinocyte 
apoptosis. This severe condition of CLE, mostly have to be treated with IVIG and/or systemic 
corticosteroids [16].
Moreover, there have been other primary blistering disorders reported in association with LE, 
including pemphigus vulgaris, LABD, porphyria cutanea tarda, fixed drug eruption (FDE), 
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Stevens-Johnson syndrome (SJS), TEN as well. FDE lesions are characterized by sharply mar-
ginated, round- or oval-shaped lesions that can have central bullae [8]. These bullae may be 
seen widespread like TEN. To differentiate FDE from other bullous presentations, some clues 
are important to know. In FDE, a drug history must be exist like SJS/TEN but, in FDE patients 
recurrent episodes are typically seen in minutes to hours after re-exposure to a particular 
medication, whereas in SJS/TEN, recurrent episodes due to the medication can occur in as 
early as 2 days. FDE lesions occur in the same location as previous episode. Histopathological 
findings of FDE lesions show superficial and deep perivascular mixed infiltrate with lympho-
cytes, neutrophils, eosinophils, and histiocytes. However, in TEN, typically there is usually 
only a superficial perivascular infiltrate with lymphocytes and histiocytes. DIF of FDE lesions 
is not well described; linear IgG and C3 deposition along the BMZ, perivascular, and intercel-
lular IgG and C3 were reported. Thus, in addition to history, clinical feature, and histopathol-
ogy, DIF method helps to rule out FDE from BSLE [64].
In SJS/TEN, which have a significant mortality risk, there can be extensive skin involvement 
with especially annular lesions and moderate-severe mucosal involvement with a clear drug 
association. However, in BSLE generalized skin involvement is rarely seen and mucosal 
involvement is uncommon. Also, in BSLE there has been no known drug association either. 
Prognosis is poor in SJS/TEN; in BSLE prognosis depends on the systemic components of 
SLE [24, 25, 65]. But differentiation from these diseases depends primarily on history, clinical 
features, histologic findings, and DIF tests [66–68].
As mentioned previously, DH is also involved in the differential diagnosis of BSLE. DH, also 
known as Duhring’s disease, is a chronic autoimmune bullous disease, associated with celiac 
disease and gluten sensitivity. It is claimed that DH can be regarded as a skin manifestation 
of gluten sensitivity, a systemic disorder capable of affecting multiple organs. [69]. DH is 
characterized by grouped erythematous excoriated papules or plaques with small, clustered 
herpetiform vesicles, and tense blisters distributed symmetrically over extensor surfaces—
particularly elbows, knees, buttocks, and shoulders, rarely on the oral mucosa. The eruption 
of DH most often begins between the ages of 15 and 50 years and persists indefinitely. Patients 
have generally intense itching and burning sensation [70]. There is an association with the 
genotypes HLA DR3, HLA DQw2, found in 80–90% of cases. HLA-Al, -B8 are also found to 
be as related genotypes. Celiac disease has association with HLA-B8, HLA-DR3, and HLA-
DQw2 histocompatibility complex antigens as well. This means DH and celiac disease have 
a common immunogenetic background [71]. Morbidity is mainly related to the intense pruri-
tus, scratching, discomfort, commonly seen superimposed infections. Also, systemic compli-
cations are related to the associated gluten-sensitive enteropathy. Celiac disease is accepted 
to be present in all patients with DH, but some of these patients have subclinical gastrointesti-
nal disease with no symptoms, only histological findings as well. Gastrointestinal symptoms 
of patients with DH are milder than those seen in patients with celiac disease without skin 
lesions [72]. Histopathologic examination of the lesion shows subepithelial bulla with neu-
trophils in the dermal papillae, fibrin deposition, and edema. Usually, papillary neutrophilic 
microabscesses progress to subepidermal vacuolization and vesicle formation. In DIF micros-
copy granular IgA deposits in dermal papillae of perilesional skin is found [48]. The clinical 
and histopathological features of DH can be the same as those of BSLE. Extensor surface 
involvement is less common in BSLE and pruritus is usually absent or mild [8]. Contrary to 
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BSLE, in DH the markers of gluten sensitivity: anti-gliadin, anti-endomysium, and anti-tissue 
transglutaminase antibodies are important characteristics, and gluten-free diet, dapsone, and 
sulfone therapy are the main choices of treatment. In BSLE, IgG and IgM can be found in addi-
tion to IgA in the BMZ. Thus, this finding helps to differentiate BSLE from DH, in which only 
IgA deposits are observed [48].
LABD is an autoimmune mucocutaneous disorder that characterized by subepithelial bullae 
caused by IgA autoantibodies. These autoantibodies are directed against BMZ and the genetic 
basis of the disease is found related to HLA Cw7. Although it was previously confused with DH; 
now they are well-recognized distinct entities. Furthermore, in contrast to DH, there is no asso-
ciation with gluten-sensitive enteropathy, and the gluten-free diet is ineffective in LABD disease 
as well [73]. Bullae may be clear or hemorrhagic, tense like BP bullae, vary in size, and frequently 
tend to form annular or polycyclic plaques and they have risen out of normal skin, or on an ery-
thematous or urticarial base. LABD can be seen at any age, but there are two peaks of onset: at 
40–60 years of age and in children of preschool age. It has a heterogeneous clinic based on age 
of onset, clinical features, and distribution. In children, vesiculobullous lesions are mainly seen 
on the lower abdomen and the perineal area, whereas face, hands, and feet are rarely involved. 
Blisters commonly occur in a “cluster of jewels” pattern [74]. However, in adults, LABD lesions 
mainly involve extensor surfaces, buttocks, trunk, and the perioral area. These lesions are usu-
ally highly itchy. All mucous membranes may be involved; particularly, the oral cavity and eyes 
are the most common affected mucosal area. Lesions of the oral cavity cause generally severe 
pain. LABD may be idiopathic or associated with SLE [75], inflammatory bowel disease (IBD), 
Crohn’s disease, and ulcerative colitis [76], infections [77], malignancies-particularly hemato-
logic cancers [78], and drugs such as vancomycin, captopril, acetaminophen, and phenytoin [79]. 
Physical trauma and ultraviolet exposure have been also reported as triggering factors in the 
pathogenesis of LABD [80]; however, in the literature, most cases of LABD are idiopathic [7].
The histopathologic examinations of LABD lesions show a subepithelial blister with a predomi-
nant neutrophilic infiltrate—occasionally eosinophils and mononuclear cells—in the upper epi-
dermis that forms papillary microabscesses. The DIF examination of LABD shows the presence 
of IgA deposits along the BMZ in a linear pattern. IIF generally shows a variable positivity of 
30–50% of circulating IgA autoantibodies in LABD patients [81]. Usually, dramatic response to 
sulfones or sulfonamide is seen in LABD patients. In idiopathic cases of LABD, dapsone treat-
ment is the best choice [82]. Based on clinical and histologic features alone, it may be hard to 
distinguish LABD from BSLE. Therefore, one or more advanced methods such as DIF, IIF, salt-
split skin, Western immunoblotting, and IEM should be used to differentiate these diseases [83].
1.10. Treatment
For other cutaneous manifestations of SLE disease, the main treatments are topical and sys-
temic steroids and antimalarials [5]. Differently from these cutaneous lesions, BSLE lesions 
are often recalcitrant to the high dose systemic corticosteroids which are used to treat the 
other systemic manifestations of SLE [1]. The primary treatment choice in BSLE is dapsone 
and this is one of distinguishing features of BSLE from most of other autoimmune bullous 
dermatoses. Even with low doses (25–50 mg/day) of dapsone, improvement of skin lesions 
is expected to be observed within the first 24–48 h of the therapy. However, during dapsone 
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therapy, improvement in the systemic involvement often does not parallel the cutaneous 
response. For example, Kettler et al. [84] reported a child case of BSLE whose cutaneous 
eruptions responded rapidly to the treatment of dapsone, whereas the oral ulcers did not 
improve without prednisone therapy. Beside this, they used prednisone treatment alone, but 
cutaneous eruption of the patient did not improve either. Oral ulcers healed after starting the 
combination therapy of dapsone, prednisone, and sulfapyridine. As distinct from most of 
BSLE cases, Alarcón et al. reported a case of BSLE whose rashes worsened by dapsone treat-
ment. The patient was recovered by systemic steroid therapy [85].
Total regression of cutaneous lesions is generally seen within weeks [1, 8, 27, 37, 86]. Dapsone 
has several mechanisms that mainly act via interference with the chemotaxis-adherence-cytotoxic 
enzymes of neutrophils [87].
The main adverse effects of dapsone treatment are methemoglobinemia, hepatitis, headache, 
motor neuropathy, exfoliative dermatitis, and fatal agranulocytosis. Especially patients with 
glucose-6-phosphate dehydrogenase deficiency may present with severe hemolysis after dap-
sone treatment. Therefore, patients should be tested for this enzyme deficiency before being 
treated with dapsone. Furthermore, in BSLE patients, the risk of hemolysis is higher than DH 
patients. So, it is recommended that the dapsone dosage per day should not exceed 1.5 mg/kg 
to minimize this side effect [21, 87]. Interestingly, it has been reported that in some cases with 
BSLE, dapsone treatment lead to exacerbation of lesions [5, 85].
Dapsone can be stopped by tapering, but there is no exact time to stop the treatment and usu-
ally there has been no relapse reported in BSLE patients [8, 88]. Recurrences are often seen rapid 
after the withdrawal of dapsone. However, restarting the treatment can provide prompt remis-
sion [88]. In general, discontinuance of dapsone therapy is usually recommended after 1 year.
Furthermore, sometimes—especially if systemic involvement is significant such as nephri-
tis—dapsone is not sufficient. Steroid treatments or other immunomodulatory treatments 
such as azathioprine, methotrexate, cyclophosphamide, antimalarial agents, and MMF can be 
used for these patients or for the patients who fail to respond to dapsone or have intolerance 
to dapsone [4, 5]. In addition, rituximab was recently reported to be effective in cases of BSLE 
with no response to dapsone and other immunomodulatory treatments [15, 18, 89]. Anyanwu 
et al. reported an oral BSLE case treated successfully with rituximab [90].
Moreover, Pehr [91] reported that in the youngest case of BSLE, the combination of MMF 
and erythromycin was found to be effective. Interestingly, in that case, neither dapsone nor 
medium- to high-dose systemic steroid treatments provided benefit. Near-perfect control of 
BSLE was provided in some cases after combination therapy of erythromycin and MMF was 
administered. MMF had been used in other bullous diseases of children with good results and 
for systemic manifestations of childhood LE [92–94]. MMF acts via blocking de novo purine 
synthesis, thereby interfering with lymphocyte proliferation. Although erythromycin is an 
antibiotic, it also probably acts as an anti-inflammatory agent via interference with matrix 
metalloproteinase 9. Thus, MMF used in combination with erythromycin is thought to have 
synergistic effect. Furthermore, in the previous cases of bullous LE in childhood, following 
treatments were used: systemic steroids, dapsone, azathioprine, cyclophosphamide, sulfa-
pyridine, and hydroxychloroquine [91, 95, 96].
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Also, there have been some reported BSLE cases that were successfully treated with IVIG 
therapy [13, 97, 98].
If the treatment of BSLE is summarized, after diagnosis of BSLE was made based on criteria 
first of all, it should be asked whether systemic complications of SLE are present or not. If 
answer is no, then dapsone treatment can be first choice drug with or without immunosup-
pressants. If answer is yes, a systemic complication is present; then corticosteroids, azathio-
prine, cyclophosphamide, antimalarials, methotrexate, MMF and rituximab, IVIG may be the 
drug choices and they could be applied alone or in combination [15].
1.11. Prognosis
Treatment with dapsone is successful in most cases of BSLE [5]. Frequently, lesions resolve 
spontaneously in less than 1 year and, to prevent recurrences, discontinuance of dapsone 
therapy is usually recommended after 1 year [88]. In some BSLE cases with severe systemic 
manifestations of SLE, prognosis is similar to systemic SLE. But, the development of BSLE in 
patients with SLE does not cause to increased mortality. In these patients, immunosuppres-
sants and immunomodulatory drugs are preferred rather than dapsone [5, 6].
2. Cicatricial pemphigoid
2.1. Introduction
Cicatricial pemphigoid, (synonyms: mucous membrane pemphigoid, oral pemphigoid, des-
quamative gingivitis, ocular cicatricial pemphigoid) is an inflammatory disorder characterized 
by subepidermal blisters. CP affects particularly mucous membranes but cutaneous involve-
ment can also be seen in some cases [99, 100]. The lesions usually heal with scarring, and CP 
may cause fatal outcomes such as airway obstruction. So, clinicians should recognize this rare 
entity as immediate as possible to prevent its complications [99]. CP patients must be evaluated 
by multidisciplinary team approach which involves primary care physicians, dentists, oph-
thalmologists, dermatologists, gynecologists, gastroenterologists, and otolaryngologists [100].
2.2. Epidemiology
CP is the second most frequent subepidermal blistering disease. It usually affects the older 
population (60–80 years of age), and children are rarely encountered as well. CP is seen 
approximately 1.5–2 times more in women than men [101]. There are about 20 cases of child-
hood onset CP reported, of which the youngest is 10 months old [102–104]. There is no known 
racial or geographic predilection [105].
The actual incidence of CP is unknown, however it was found as about 1.3–2.0/million/year in 
France and also a prevalence of 24.6/million in 2014 was reported in Germany [106, 107]. For 
ocular pemphigoid—a CP type with conjunctival involvement exclusively—an incidence of 
one new case/million/year was reported in England as well [108, 109].
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2.3. Etiopathogenesis
The etiopathogenesis is still unknown; however, it is thought that environmental factors 
combined with genetic susceptibility lead to CP. There have been some reported cases of CP 
triggered by human immunodeficiency virus, diphtheria vaccination, and some medications 
such as methyldopa, clonidine, and D-penicillamine [110, 111]. In addition, other autoim-
mune diseases may occur more frequently in patients with CP [112]. Moreover, some bullous 
diseases may indicate the presence of an underlying malignancy. Especially, lymphomas and 
epithelial malignancies should be ruled out in autoimmune bullous diseases as well as MMP 
[113]. A possible association with HLA haplotypes (HLADQB1* 0301) and HLA-4 have been 
described in CP patients [105, 114]. It is suggested that a genotype of the interleukin (IL) 4 
receptor A-1902 A/A, which is found in 90% of patients with oral pemphigoid, reduces the 
response to IL-4 and this may be connected with low risk of scarring in oral involvement [115].
Production of autoantibodies responsible for the disease is initiated by the loss of immuno-
logic tolerance against the components of the basal membrane. A variety of different autoanti-
gens including BP antigen (Ag) 230 (BPAg1, a 230-kDa protein, BP1), the BPAg180 (a 180-kDa 
protein, BP2), Lam-332 (also called epiligrin), integrin α6, integrin β4, the 97/120-kDa LABD 
antigen, type VII collagen, and some antigens such as a 45-kDa protein, uncein, a 168-kDa epi-
thelial protein, and a 120-kDa epithelial protein have been described in patients with CP. The 
two major autoantigens of CP are BPAg2 and Lam-332. BPAg1 and BPAg2 are components of 
hemidesmosome structure. BPAg1 is an intracellular protein implicated in the organization of 
the keratin filament network; whereas, BPAg2 and integrin α6-β4 are transmembrane proteins 
that contribute to the assembly and stabilization of hemidesmosomes. Autoantibodies predomi-
nantly identify the C-terminal epitopes of BP180, but, NC16A is the second immunodominant 
domain. Lam-332 establishes connection between anchoring ligaments and transmembrane 
proteins. It is a heterotrimeric glycoprotein situated on the BMZ, including α3, β3, and γ2 sub-
units. Most of CP patients with anti-Lam-332 antibodies were reported to have autoantibodies 
to the α3 and γ2 subunits, and less frequently to the β3 subunit of the Lam-332 [99, 116–118].
Complement is activated by antigen antibody ligation and the cytokine/chemokine release 
leads lysis of cell membrane, infiltration, and degranulation of effector cells that cause clinical 
inflammation and tissue destruction. Thereafter, aggregation of inflammatory cells induces 
subsequent activation of fibroblasts. Fibroblasts multiply and secrete collagen, and by this 
action, subepithelial fibrosis has been started. Cytokines, particularly transforming growth 
factor beta (TGF-β), IL-13, tumor necrosis factor (TNF-α) may play a significant role in the 
pathogenesis of conjunctival scar tissue formation in CP patients [119, 120].
2.4. Clinical features
The oral mucosa is the most affected part of the body, ocular, nasal, nasopharyngeal, anogeni-
tal, laryngeal, esophageal mucosa, and skin can be involved. If there is cutaneous involve-
ment, mostly skin of head and upper body are affected. More than one mucosal region may 
be simultaneously affected. In CP cases with predominantly mucosal involvement, scarring is 
more often. CP lesions are recalcitrant to treatment and this is a distinctive feature of CP from 
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other bullous diseases. Although scarring is an important clinical feature of CP, it may not be 
present in areas such as the oral mucosa. Complications such as blindness, airway obstruction 
are observed on the areas where the disease leads to scar formation [99, 121].
The distribution of disease may be local or widespread. The severity of the disease is associ-
ated with the magnitude of effected area. Localized lesions may progress to the extensive 
disease. The patients with only oral mucosa and/or skin involvement have less risk for scar-
ring and this group is defined as “low-risk” CP patients. On the contrary, “high-risk” patients 
have lesions in any of the following sites: ocular, nasopharyngeal, esophageal, laryngeal, and 
genital mucosa [99, 122, 123].
Murrell and colleagues have established the Mucous Membrane Pemphigoid Disease Area 
Index for use in clinical studies for intervention and evaluation of CP patients (Table 2) [124].
Oral mucosa is the most frequently involved and is often the first (or sometimes solely) affected 
region in patients with CP. Desquamative gingivitis is generally the first finding of oral 
CP. Painful, erosive/blistering lesions occur often in the gingival, buccal mucosa, and palatal 
region. Tongue, lips, and alveolar ridge are rarely affected. The lesions can frequently recur at the 
same region. Erosions, desquamative gingivitis are observed in the acute period of the oral dis-
ease, whereas complications such as delicate pattern of reticulate scarring, periodontal ligament 
damage, loss of bone mass, teeth loss, or adhesions are noted during the chronic period [121].
Ocular involvement is also seen commonly in patients with CP. Isolated ocular involvement is 
present in some patients. Generally, the mean age of onset is 65 in this clinical subtype, but it 
is more aggressive in younger patients. Ocular findings may be nonspecific in the early stages 
of the disease (such as burning, dryness, photophobia, or foreign body sensation). Blisters 
are rarely observed. The ocular involvement is usually unilateral at the beginning, but the 
opposite eye is also involved in following years. Ocular CP may result in development of 
symblepharon, ankyloblepharon, entropion, trichiasis, corneal ulceration, neovasculariza-
tion, and blindness. Ocular CP should be evaluated by an experienced ophthalmologist and 
distinguished from other ophthalmologic diseases. Slit-lamp examx may be useful for early 
diagnosis of ocular CP [99, 125].
Genital involvement in males generally results in erosions on the glans, urethral strictures, 
and phimosis [126]. Interestingly, female patients may be asymptomatic. But erosions on the 
labia minora/majora, dysuria, vaginal discomfort, dyspareunia may be present and conse-
quently fusion of the labias may be seen [127].
Nasopharyngeal involvement is another clinical output of CP and findings such as epistaxis, 
dysphagia, dysphonia, nasal obstruction, and nasal crusting can be seen [128]. Laryngeal 
involvement may cause fatal airway obstruction requiring tracheostomy [125]. There is 
esophageal involvement in approximately 2–7% of patients that may cause dysphagia, ody-
nophagia, aspiration, strictures, and malnutrition as well [129].
Skin involvement is detected in 25–35% of CP patients. Clinical presentation is frequently 
small, tense vesicles, or bullae on the scalp, head, neck, and upper trunk. The cutaneous 
lesions are usually smaller in size and sometimes recur in the same region. Accompanying 
atrophic scars and milia can be observed in the lesion sites [121].
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CP is divided into subsets according to antibody profiles and sites of involvement. The disease 
caused by Lam-332 antibodies is called antiepilegrin CP (AECP). AECP is estimated to comprise 
of 5–20% patients of CP. The patients in this group are clinically indistinguishable from other 
forms of cicatricial pemphigoid and some of these patients may occasionally have antibod-
ies directed against Lam-331. Egan et al. demonstrated that 100% of the patients had mucous 
membrane involvement and 86% had mild to moderate skin involvement in AECP [130, 131].
Some of the patients with CP may have restricted disease with ocular mucosa involvement 
or may have a clinical course that predominantly not only affects the ocular mucosa, but also 
involves other mucosal sites. This form of disease is called ocular CP and antibodies to a por-
tion of the intracytoplasmic component of human integrin-β4 and/or BP-180 are detected in 
Disease activity Damage
Erosions-blisters and 
new erythema in ears, 
forehead, rest of the face, 
neck, chest, abdomen, 
shoulders, buttocks, arms 
and hands, legs and feet, 
anal, genital sites





Present = 11 = 1–3 lesions; furthest 1 lesion >2 cm in any 
diametery, none >6 cm;
2 = 2–3 lesions, at least 2 lesions >2 cm diameter, 
none >6 cm;
3= >3 lesions, none >6 cm diameter;
5= >3 lesions, and/or at least 1 lesions >6 cm,
6= > 3 lesions, and/or at least 1 lesions >16 cm 
diameter of entire are
Erosions-blisters and new 
erythema in scalp





Present = 11 = 1 quadrant
2 = 2 quadrants
3 = 3 quadrants
4 = affects complete scalp
10 = at least 1 lesion >6 cm





Present = 11 = Light pink
2 = Moderate pink
5 = Dark pink
10 = Bright red
Erosions/blisters in other 
mucosa





Present = 11 = 1 lesion
2 = 2–3 lesions
5= > 3 lesions or 2 lesions >2 cm
10 = whole area
Table 2. Mucous membrane pemphigoid disease area index [124].
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this group of patients [132]. Another variant within the CP phenotype is anti-BP180 MMP, 
where the patients have circulating IgG antibodies to BP antigens. Both of the skin and 
mucous membranes are involved in this variant. BP180 C-terminal domain and BP180 NC16a 
domain are considered to be the major antigenic domains in anti-BP180 MMP [133].
Another subset of CP is called oral pemphigoid, in which the autoantibodies to human alpha-6 
integrin subunit are thought to be responsible for the disease. The patients with this type of CP 
have limited disease to the oral mucosa with no skin or other mucosal involvement [134, 135].
CP is rarely seen in children and it is called childhood CP. Ocular and genital mucosa involve-
ment is common in children. Linear IgA deposits was detected and reported like LABD. In 
view of the fact that conjunctival scarring can also be seen in patients with LABD, it has been 
discussed whether CP and LABD should be classified as the same disease or whether they are 
different entities [136] .
Brunsting-Perry CP is a rare variant of CP characterized by blisters, hemorrhagic crusts, and 
mainly atrophic scars. The lesions are observed predominantly located on the head, neck, 
scalp, and upper aspects of the trunk with only mild or no mucosal involvement. There is no 
specific antigen of Brunsting-Perry CP. This variant is seen in middle-aged or elderly patients, 
with a male predominance [137, 138]. Some authors have suggested that Brunsting-Perry CP 
may a clinical variant of EBA [139].
2.5. Diagnosis
Diagnosis of CP is made based on clinical, histological, and immunopathological findings. 
The diagnosis of CP is often difficult, especially in early stages, because of variations in clini-
cal presentation and on histopathological examination.
Histopathological examination of CP lesions shows subepidermal split (without acantholy-
sis) and dermal leukocytic infiltrations mostly composed of lymphocytes, histiocytes, as well 
as variable number of neutrophils and eosinophils. The inflammatory infiltrates in mucosal 
lesions contain plasma cells. Mast cells may be detected in biopsy specimens of the conjunc-
tiva as well. Similar findings can be seen in BP, LABD and EBA. Histopathological examina-
tion of older lesions shows fibroblast proliferation and fibrosis [140].
The electron microscopic examination shows epithelian findings including intracellular 
edema, decreased number of goblet cells, granular materials and fragmentation, duplica-
tion, thickening in BMZ. According to Thorne et al., the sensitivity and specificity of electron 
microscopy in ocular CP were found as 51 and 72%, respectively [141].
IEM studies have shown that the immune deposits are located in lamina lucida, lamina densa, 
hemidesmosomes, and basal keratinocyte cytoplasm [140].
DIF microscopy characteristically shows a continuous, linear n-serrated pattern of IgG (fre-
quently IgG4), C3, less commonly IgA, IgM, and fibrin or a combination of these along the 
BMZ. DIF is the gold standard test for diagnosis of CP, but it is also known to have high false 
negative rates especially in ocular CP. Shimanovich et al. found that DIF staining was positive in 
74 of 78 patients (95%); however, multiple and recurrent biopsies were taken from the patients. 
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The sensitivity of DIF microscopy was increased with multiple and repeated biopsies. [142]. 
Power et al. claims that using immunohistochemistry which includes immunoperoxidase tech-
nique may increase the sensitivity of conjunctival biopsy in the diagnosis of ocular CP [143, 144].
ELISA systems and IIF can be used to determine circulating antibodies. Normal human epithelial 
substrate (e.g., 1.0 M sodium chloride–split skin) is used in IIF and IIF reveals binding to the roof 
(epidermal) or floor (dermal) of the blister depending on the antigen targeted. While, patients 
with integrin and BP180 autoantibodies display circulating IgG autoantibodies that bind to the 
epidermal side, Lam-332 autoantibodies bind to dermal side of salt-split skin by IIF [99, 140].
According to Amber’s study, which included the patients with positive immunoblot or 
immunoprecipitation to NC16a, ELISA test including both NC16a and C-terminal portion of 
BP180 demonstrated 73% sensitivity and 93% specificity. But, when they tested IgG reactivity 
against the C-terminal domain of BP180 in the same patients, both the sensitivity and specific-
ity decreased to 43 and 56%, respectively. The sensitivity of ELISA reached 75% in the patients 
who have IgG reactivity against the Lam-332-a3 subunit [145]. According to another study, 
the titer of IgA antibodies to NC16a in saliva was found correlated with sera [144].
Serum autoantibodies against BP230 are more frequently detected when anti-Lam-332 auto-
antibodies are also present. This association was thought to be possibly related to epitope 
spreading [107]. Bekou’s study showed that 78% of patients with CP had serum anti-Lam-332 
autoantibodies. Sensitivity and specificity of the Lam-332 ELISA for CP were 75 and 84.3%, 
respectively, in the same study [146].
Some authors have also suggested that a dual IgG and IgA serum anti-BMZ antibodies are 
associated with a more severe disease. Additionally, serum titers of anti-BMZ IgG autoan-
tibody often correlate well with disease severity [147]. LAD-1 is an extracellular C-terminal 
domain of BP180. Dual IgG and IgA reactivity with BP180 and LAD-1 was found to be associ-
ated with severe phenotype [148].
Also, there is another popular technique, BIOCHIP mosaic slides have been found to be use-
ful in screening autoantibodies in autoimmune bullous diseases (AIBD). These consisting of 
different antigen substrates (monkey esophagus, primate salt-split skin, recombinant BP180 
NC16A, membrane-bound Dsg 1 ectodomain, Dsg 3 ectodomain, and the C-terminal globular 
domain of BP230) allow polyvalent IF tests and provide antibody profiles in a single incuba-
tion. Technically, it is a modified-IIF, wherein serum from patients with suspected AIBD is 
added to these slides and examined under fluorescence microscopy. BIOCHIP technique is a 
simple, standardized, and readily available technique which is useful to screen autoantibod-
ies in AIBDs as well as to identify the target antigen [149].
2.6. Differential diagnosis
Disorders that should be differentiated from CP include pemphigus, other subepidermal 
immunobullous disease, erythema multiforme, SJS, lupus erythematosus, lichen planus, 
lichen sclerosus (especially in the anogenital area), drug-induced hypersensitivity reaction. 
If there is ocular involvement, other conditions causing fibrosis in the conjunctiva should be 
considered, such as Sjogren’s syndrome, scleroderma, severe chronic infectious conjunctivitis, 
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burns. Some drugs (e.g., pilocarpine, guanethidine, ephedrine, idoxuridine, epidermal 
growth-factor receptor tyrosine kinase inhibitors) may cause inflammation and fibrosis in the 
conjunctiva as well. This is called pseudopemphigoid. These patients are clinically indistin-
guishable from other autoimmune bullous diseases. Specialized immunopathologic studies 
and/or IEM may be required for diagnosis [112, 125]. It also has been reported that ocular CP 
developed after Steven Johnson syndrome and Lyell syndrome in some cases. It is thought 
that the chronic eye surface damage in these cases may trigger the autoimmune process [150].
2.7. Treatment
The main purpose of CP therapy is to prevent scar development, complications such as blindness 
and airway obstruction. Treatment should be initiated in the early period to prevent complica-
tions. Co-operation of oral medicine experts, dermatologists, ophthalmologists, otolaryngolo-
gists, and gastroenterologists is important for treatment. The factors determining the treatment 
regimen in CP are localization, disease severity, and progression rate. CP patients were divided 
into two groups according to an international consensus. The first group includes patients with 
oral mucosa and/or skin involvement (low risk); second group includes ocular, laryngeal, esoph-
ageal, or genital involvement (high risk) patients. Topical treatment is an initial choice for low-
risk patients. However, a more aggressive treatment plan is proposed for high-risk patients even 
in early period of disease [99]. For the low-risk patients, an initial treatment of moderate-high 
potency topical corticosteroid can be tried. Depending on the condition of the patient, dapsone 
(50–200 mg/day), tetracycline (1–2 g/day)/nicotinamide (2–2.5 g/day), sulphamethoxypyrida-
zine (0.5–1 g/day), sulphapyridine (0.25–1 g/dl) can be administered. In the condition of partial 
response to treatment or progressive disease, systemic corticosteroids are needed for treatment 
of the patients with no contraindication. If there is an existing contraindication about systemic 
corticosteroid, other medications like azathioprine, mycophenolat mofetil, cyclophosphamid 
can be used. IVIG and/or rituximab are the options if there is no response to other mentioned 
drugs. The treatment begins with systemic corticosteroid, azathioprine or MMF in patients with 
severe clinic/high risk. The agents may be changed according to clinical course [151].
High potency topical glucocorticoids (fluocinonide, clobetasol propionate, and betamethasone 
dipropionate) are the first choice agents. They can be applied as a spray, gel or ointment base. 
Mouthwash (dexametasone 100 mg/ml, 5 ml per rinse) can be used by shaking and spitting 
for oral lesions. Oral insertable prosthetic device may facilitate the symptoms for oral mucosa. 
Intralesional corticosteroid therapy may be used instead of topical corticosteroid. Systemic 
absorption should be considered during application of topical corticosteroid. Antifungal treat-
ments should be used in cases with secondary candidiasis infection [125, 151]. Patients should 
be recommended to improve oral hygiene and try to avoid rigid foods. Topical formulations 
of tacrolimus, cyclosporin, mitomicin C (topical and subconjunctival applications) have been 
described for advanced treatment of CP [152, 153].
Systemic corticosteroid (prednisolone 0.5–1.5 mg/kg/day) have a rapid onset of action; how-
ever, the adverse effects such as hyperglycemia, hypertension, hyperlipidemia, osteoporosis, 
gastric ulcers, secondary infections, and alterations of mood or even psychosis associated 
with long-term use limit their value [151, 154].
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Dapsone therapy is accepted to be the first line of treatment for mild to moderate ocular 
CP. Adverse effects include hemolysis, methemoglobinemia, dapsone hypersensitivity syn-
drome (fever, lymphadenopathy, hepatic damage, and generalized erythematous pustules). 
Patients should be monitored periodically for these side effects [155].
Biologic agents including etanercept, rituximab, infliximab, and daclizumab can be effec-
tive in controlling severe CP cases that are resistant to conventional immunosuppressive 
agents [156–158]. Lymphoma protocol is used for rituximab therapy, which involves a dose 
of 375 mg/m2 administered weekly for four consecutive weeks. In patients treated with ritux-
imab, the clinical response was usually obtained 3–6 months after the first dose [159, 160].
IVIG therapy (1–3 g/kg/cycle) can be used in treatment of CP patients who do not respond 
to conventional therapy or are unable to use them because of various side effects. For recal-
citrant ocular CP, combination therapy of rituximab and IVIG is a potent treatment regimen. 
The most common side effect is headache, followed by nausea [161, 162]. Plasmapheresis has 
found to be effective in some recalcitrant patients, as well [163].
Eyelid abnormalities such as trichiasis, distichiasis, entropion, lagophthalmos, and symbleph-
aron stenosis of the upper airway, esophageal, and anogenital stricture may need to be man-
aged surgically. Surgical management aims to achieve temporary symptomatic relief and is 
not a curative treatment for CP [132].
2.8. Prognosis
CP is typically a chronic and progressive disease. CP rarely undergoes spontaneous remis-
sion and relapses are seen commonly. Ocular, nasopharyngeal, esophageal, and laryngeal 
involvement are related with high risk. Anti-Lam-332 antibodies are associated with severe 
disease and internal malignant neoplasms including solid tumors and lymphomas. The risk 
of cancer is highest during the first year of disease [107]. Egan’s study demonstrated that 
the relative risk for cancer was 15.4 in the first year of disease onset. Adenocarcinoma (lung, 
colon, stomach, endometrial) was frequently detected in this study [131]. In a study, various 
internal malignancies were found in BP180-CP, but the relationship between BP180-CP and 
internal malignancy is still unclear [133].
3. Conclusion
BSLE and CP are rare autoimmune bullous disorders that have their own characteristics. But 
sometimes, BSLE may resemble other autoimmune bullous disorders and CLE associated bul-
lae. Moreover, BSLE may be related to increased systemic disease activity of SLE, especially 
nephritis. So, diagnosis of BSLE is very important and accurate diagnosis requires a high 
index of clinical suspicion. Scarring of the lesions in CP causes significant complications such 
as blindness. Early diagnosis and early treatment have a critical role for preventing the scar 
development. Systemic adjuvant immunosuppressive therapy is required for patients with 
progressive disease.
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